€500m charge as Degussa restructures
Degussa has been forced to take a €500 million charge in its fine chemicals business unit as it copes with the current adverse operating environment.
Degussa has been forced to take a €500 million charge in its fine chemicals business unit as it copes with the current adverse operating environment.
A new study from PharmaVentures notes that M&A among pharma firms worldwide has declined while biotech-biotech alliances have risen dramatically.
UK-based BioProgress has elected to sell the rights to one of its NROBE non-gelatine film technologies to FMC BioPolymer after deciding that the program would benefit from being in the hands of a bigger partner.
US life science chemicals company Cambrex has altered the terms of its agreement to sell Rutherford Chemicals and will make a slightly higher loss on the new transaction.
Advanced Labelling Systems (ALS) has launched the T-series tube labeller, which is claimed to offer a cost effective alternative to direct tube printing for pharmaceutical applications.